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Research Commentary
Warburg et al1 were the first to report markedly elevated levels of the glycolytic enzyme hexokinase (HK) 
in aggressive tumors. Indeed, increased HK expression in 
cancer cells was mechanistically linked to their resilience 
against apoptosis. These pioneering studies established a 
central role for HK expression in cancer biology. In recent 
years, we extended the role of HK isoforms from the patho-
physiology of cancer to that of ischemic heart disease.2,3 
Specifically, we showed that the expression and subcellular 
distribution of the HK isozyme, HKII, is a major determinant 
of ischemia-reperfusion (IR) injury.4–6 Furthermore, binding 
of HKII to mitochondria, which is increased by ischemic pre-
conditioning (IPC),2,5 protects against oxidative stress and IR 
injury, potentially by limiting cellular reactive oxygen species 
levels7 and preserving the mitochondrial membrane potential 
(ΔΨ
m
).4
In our most recent work, we undertook a small molecule 
approach designed to acutely dislodge HKII from mitochon-
dria.4 Specifically, we used a transactivating transcriptional 
factor peptide (TAT-HKII) that contains the mitochondrial 
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Rationale: We have shown that partial dissociation of hexokinase II (HKII) from mitochondria in the intact heart 
using low-dose transactivating transcriptional factor (TAT)-HKII (200 nmol/L) prevents the cardioprotective 
effects of ischemic preconditioning, whereas high-dose TAT-HKII (10 μmol/L) administration results in rapid 
myocardial dysfunction, mitochondrial depolarization, and disintegration. In this issue of Circulation Research, 
Pasdois et al argue that the deleterious effects of TAT-HKII administration on cardiac function are likely because 
of vasoconstriction and ensuing ischemia.
Objective: To investigate whether altered vascular function and ensuing ischemia recapitulate the deleterious effects 
of TAT-HKII in intact myocardium.
Methods and Results: Using a variety of complementary techniques, including mitochondrial membrane potential 
(ΔΨm) imaging, high-resolution optical action potential mapping, analysis of lactate production, nicotinamide 
adenine dinucleotide epifluorescence, lactate dehydrogenase release, and electron microscopy, we provide direct 
evidence that refutes the notion that acute myocardial dysfunction by high-dose TAT-HKII peptide administration 
is a consequence of impaired vascular function. Moreover, we demonstrate that low-dose TAT-HKII treatment, 
which abrogates the protective effects of ischemic preconditioning, is not associated with ischemia or ischemic 
injury.
Conclusions: Our findings challenge the notion that the effects of TAT-HKII are attributable to impaired 
vascular function and ensuing ischemia, thereby lending further credence to the role of mitochondria-bound 
HKII as a critical regulator of cardiac function, ischemia-reperfusion injury, and cardioprotection by ischemic 
preconditioning. (Circ Res. 2013;112:e8-e13.)
Key Words: hexokinase ◼ ischemia ◼ mitochondrial membrane potential ◼ TAT peptide ◼ vasoconstriction
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binding motif of HKII8,9 to investigate the functional impact 
of reduced mitochondrial-HKII association in the intact heart. 
Using electron microscopy (EM) and HKII immunogold la-
beling, we demonstrated that treatment of hearts with TAT-
HKII reduced mitochondrial-HKII localization.4 Using this 
pharmacological approach, we showed that pretreatment of 
hearts with low-dose TAT-HKII (200 nmol/L) abrogated the 
protective effects of IPC on IR injury. Moreover, treatment of 
hearts with high-dose TAT-HKII (10 μmol/L) caused abrupt 
contractile and electric dysfunction during basal perfusion of 
the heart. Interestingly, severe myocardial dysfunction elicited 
by TAT-HKII in the absence of additional stress (such as IR 
injury) was associated with rapid and sustained ΔΨ
m
 depo-
larization and the disintegration of mitochondrial structure. 
Because these pathological changes developed during the 
same time-course as the reduction in mitochondrial-HKII lev-
els, we concluded that the interaction between mitochondria 
and HKII is not only required for the protective effects of IPC 
but also for normal cardiac function.
In this issue of Circulation Research, Pasdois et al10 offer an 
alternative interpretation of our recent findings. Specifically, 
they argue that the deleterious effects of TAT-HKII peptide 
administration on cardiac function, including the abroga-
tion of IPC by low-dose TAT-HKII treatment and myocardial 
dysfunction with high-dose perfusion, are likely attributed to 
impaired vascular properties and ensuing ischemic damage. 
They base their conclusion, in large part, on the fact that TAT-
HKII treatment increases perfusion pressure under constant 
flow conditions and decreases perfusion flow under constant 
pressure conditions. Because Pasdois et al attributed the del-
eterious effects of TAT-HKII on myocardial function to im-
paired vascular properties and ensuing ischemia/hypoxia, 
we conducted a series of additional experiments to directly 
address the discrepancy between our conclusions and theirs. 
Specifically, we used a variety of complementary techniques 
to evaluate the presence of ischemia in our preparations and 
to compare the functional effects of ischemia and vascular 
dysfunction on metabolic and electrophysiological properties 
with those elicited by TAT-HKII treatment.
We provide direct evidence that acute myocardial dysfunc-
tion elicited by high-dose TAT-HKII administration cannot be 
ascribed to impaired vascular function or ensuing ischemia. 
Moreover, we demonstrate that low-dose TAT-HKII treatment, 
which abrogates the protective effects of IPC, is not associat-
ed with functionally significant ischemia. Taken together, our 
data refute the notion that the deleterious effects of TAT-HKII 
are attributable to impaired vascular function and ischemia, 
thereby lending further credence to our previous conclusion 
that mitochondria-bound HKII is indeed a critical regulator 
of cardiac function, IR injury, and cardioprotection by IPC in 
the intact heart.
Methods
A detailed Materials and Methods section is available in the Online 
Data Supplement.
All experiments were approved by the animal ethics commit-
tee of the Academic Medical Center, Amsterdam, The Netherlands 
or by the Animal Care and Use Committee of the Mount Sinai 
School of Medicine and adhered with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes 
of Health (NIH publication No. 85-23, revised 1996). Hearts were 
Langendorff-perfused.
TAT-Peptides
The soluble peptides MIASHMIACLFTELN(β-Ala)GYGRKKR-
RQRRRG-amide (TAT-HK) and GYGRKKRRQRRRG-amide (TAT-
CON) were produced by Pepscan presto (Lelystad, The Netherlands). 
Peptides were dissolved in perfusate Krebs–Henseleit solution and 
administered through a side-arm connected to a mixing chamber 
above the heart, at 1% of total perfusion flow.
The effect of endothelin-induced vasoconstriction on tissue struc-
ture of the mouse heart was evaluated using transmission EM of 
cryosections. High-resolution optical ΔΨ
m
 imaging using the fluo-
rescent dye tetramethylrhodamine methylester was performed in the 
intact, beating rat heart. Action potentials (APs) were measured us-
ing a charge-coupled device–based high-resolution optical mapping 
system. In a separate series of mice experiments, effluent lactate and 
lactate dehydrogenase (LDH) were measured spectrophotometrically, 
and nicotinamide adenine dinucleotide (NADH) fluorescence of the 
surface of the heart was evaluated using a videofluorometer.
Results
Myocardial Dysfunction Caused by High-Dose 
TAT-HKII Administration Cannot Be Attributed to 
Impaired Vascular Function
The study by Pasdois et al revealed a 58% reduction in perfu-
sion flow to the rat heart after administration of 2.5 μmol/L 
TAT-HKII but not TAT-con. They concluded that increased 
vascular resistance by TAT-HKII caused functionally signifi-
cant ischemia, which in turn, likely altered myocardial func-
tion. Reproducing their experimental conditions (60% flow 
reduction) and using the same species and peptide concen-
trations, we set out to formally investigate whether changes 
in perfusion flow and pressure could indeed account for the 
functional changes that we recently reported.
Differential Effects of Global Low-Flow Ischemia 
Versus High-Dose TAT-HKII Administration
Consistent with our previous findings, treatment of rat hearts 
with 2.5 μmol/L TAT-HKII (Figure 1A and 1C) caused a rapid 
(within 20 minutes) and sustained depolarization of ΔΨ
m
 
across the intact heart. Interestingly, ΔΨ
m
 depolarization was 
associated with the initiation of sustained ventricular fibril-
lation within 21.1±3.2 minutes of TAT-HKII administration 
in all treated hearts (Figure 1D, red trace). In sharp contrast, 
Non-standard Abbreviations and Acronyms
AP action potential
APD action potential duration
ΔΨm mitochondrial membrane potential
EM electron microscopy
HK hexokinase
IR ischemia-reperfusion
IPC ischemic preconditioning
LDH lactate dehydrogenase
NADH nicotinamide adenine dinucleotide
TAT transactivating transcriptional factor from human immunode-
ficiency virus 1
TAT-HKII cell permeable peptide containing hexokinase II mitochondrial 
binding motif
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global low-flow ischemia mimicking the flow reduction 
reported by Pasdois et al (ie, by 60%) completely failed to 
alter ΔΨ
m
 within the same time-course (Figure 1B and 1C). 
In fact, ΔΨ
m
 was unchanged (P=NS) even after 1 hour of low-
flow perfusion compared with baseline levels. Interestingly, 
unlike TAT-HKII administration, global low-flow ischemia to 
the rat heart was not associated with the incidence of sustained 
ventricular arrhythmias because all hearts exhibited relatively 
stable electric rhythm (3/3 hearts, Figure 1D, blue trace). In 
further support of these findings, we performed an additional 
series of studies using high-resolution optical AP mapping to 
assess whether 60% flow reduction produces adverse electro-
physiological changes that are consistent with ischemic dam-
age. Indeed, although global no-flow ischemia to the heart 
elicited significant AP duration (APD) shortening and con-
duction velocity slowing (known hallmarks of ischemia), a 
60% reduction in flow failed to alter either parameter (Online 
Figure I). These findings confirm the notion that the effects of 
TAT-HKII administration cannot be reproduced by low-flow 
conditions, which contrary to the suggestion by Pasdois et al 
do not produce adverse mitochondrial (Figure 1) or electro-
physiological (Online Figure I) alterations.
Increased Vascular Resistance Does Not Cause 
Mitochondrial Damage, Whereas 10 μmol/L TAT-
HKII Does
High-dose TAT-HKII administration to the intact heart is also 
associated with increased vascular resistance in the constant 
flow mode, as initially reported by us4 and later confirmed by 
Pasdois et al.10 It was therefore possible that the ultrastructural 
damage to mitochondria was a consequence of increased per-
fusion pressure. To address this issue, a series of mouse hearts 
were first treated with the vasoconstrictor endothelin-1 (7.5 
nmol/L). As expected, perfusion pressure rose significantly 
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Figure 1. Change in the 
normalized mitochondrial 
membrane potential (ΔΨm) 
within the intact heart elicited 
by 2.5 μmol/L TAT-HKII 
administration (A) and a 60% 
reduction in perfusion flow 
(ie, global low-flow ischemia; 
B). C, Representative ΔΨm 
contour maps measured during 
30 minutes in each group 
(TAT-HKII, low-flow ischemia, 
high-pressure perfusion). Red 
indicates depolarized ΔΨm. 
D, Representative volume-
conducted electrocardiograms 
in hearts perfused with 2.5 
μmol/L TAT-HKII (red) compared 
with low-flow ischemia (blue). 
E, Endothelin-1–mediated rise 
in perfusion pressure. F, Typical 
electron microscopic images 
obtained at low-magnification 
(top row) and high magnification 
(bottom row) of cardiac 
ultrastructure in endothelin-1 
treated hearts. G, Percentage of 
visibly damaged mitochondria 
as determined by electron 
microscopy analysis. The TAT-HKII 
data are from reference 4. H, 
 ΔΨm in hearts subjected to an 
acute elevation of perfusion 
pressure by increased flow. 
I, Average normalized ΔΨm in all 
3 groups. TAT-HKII indicates cell-
permeable peptide containing 
hexokinase II mitochondrial 
binding motif.
Nederlof et al  Lower Mitochondrial HKII Impairs Cardiac Function  e11
(173±13 mm Hg, Figure 1E) after 15 minutes of endothelin-1 
administration, comparable (P=0.66) with that elicited by 
10 μmol/L TAT-HKII (161±13 mm Hg).4 Analysis of mito-
chondrial morphology using EM on tissue sections from these 
hearts revealed normal ultrastructure (Figure 1F). On average, 
the percentage of mitochondria exhibiting abnormal morphol-
ogy in endothelin-1–treated hearts was only 1.01±1.25%, well 
below the reported value4 (78±21%) for high-dose TAT-HKII 
administration (Figure 1G).
These qualitative ultrastructural findings were corroborated 
by our functional measurements of ΔΨ
m
 within the intact 
heart. Specifically, in a series of 3 additional rat hearts, we in-
creased perfusion flow to achieve an artificially high perfusion 
pressure that mimics values reported by Pasdois et al. Despite 
a major rise in perfusion pressure (≈150 mm Hg), these hearts 
exhibited a minor reduction (<8%) in ΔΨ
m
 compared with 
>40% by TAT-HKII (Figure 1C, 1H, and 1I). On average, ΔΨ
m
 
depolarization after 30 minutes of perfusion was markedly 
greater (P<0.018) in TAT-HKII compared with high-pressure 
hearts. Taken together, our findings argue against high perfu-
sion pressure as a major cause of mitochondrial dysfunction.
Low-dose TAT-HKII Administration Does Not 
Result in Ischemia
A major finding of our previous report was the abrogation of 
the protective effects of IPC on IR injury by low-dose TAT-
HKII (200 nmol/L) administration. Pasdois et al speculated 
that this is likely attributed to ischemic damage by the pep-
tide, although their data on perfusion flow and pressure did 
not support that view. Nonetheless, we set out to determine 
whether low-dose TAT-HKII peptide administration results in 
functionally significant ischemic damage that can potentially 
confound the interpretation of our earlier findings. Using opti-
cal AP mapping, we asked whether low-dose administration 
of TAT-HKII altered ischemia-sensitive functional param-
eters (particularly APD and conduction velocity). Shown 
in Figure 2 are representative AP traces recorded during 
steady-state pacing from TAT-con (blue) and TAT-HKII (red) 
hearts (Figure 2A), as well as average APD75 and APD90 
measurements performed over a wide range of pacing cycle 
lengths (Figure 2B and 2C). Also shown are representative AP 
upstrokes indicating the delay in AP propagation (Figure 2D), 
a series of isopotential contour maps that depict the spread of 
the AP wavefront in TAT-con and TAT-HKII hearts (Figure 
2E), and average conduction velocity measurements from 
each group (Figure 2F). Clearly, low-dose TAT-HKII (200 
nmol/L) administration did not alter key electrophysiological 
properties (APD75, APD90, or conduction velocity). These 
findings argue against the development of functionally signifi-
cant ischemia with low-dose administration of the peptide that 
could potentially explain the abrogation of IPC, as speculated 
by Pasdois et al.
Ischemia Does Not Explain the Adverse Effects of 
High-Dose TAT-HKII Administration and Is Not 
Present With Low-Dose Administration
Finally, we evaluated the presence of ischemia by measur-
ing lactate production (Figure 2G) and NADH epifluores-
cence (Figure 2H and Online Figure II). LDH release was 
simultaneously measured as an independent index of cardiac 
damage (Figure 2I). Consistent with the electrophysiological 
measurements reported above, ischemia was undetectable in 
low-dose TAT-HKII hearts because NADH and lactate produc-
tion were identical in low-dose TAT-HKII and TAT-Con groups, 
further arguing against a role of ischemia in our reported4 IR 
and IPC-effects. Moreover, in support of the electrophysi-
ological measurements performed during low-flow perfusion 
(60% flow reduction), there were also no differences in any 
of the ischemia-sensitive parameters. High-dose TAT-HKII 
peptide administration, on the contrary, resulted in a minor 
increase in NADH levels (by 18%, P<0.05), a nonsignificant 
trend toward elevated lactate production (by 11%, P=NS), and 
a large significant increase in LDH release. In contrast, the 
high-pressure (endothelin) and hypoxia groups exhibited sig-
nificantly greater increases in ischemia-sensitive parameters 
(NADH and lactate production) compared with high-dose 
TAT-HKII administration. These rises in NADH and lactate 
in these groups, however, were not associated with significant 
cardiac damage (assayed by LDH release). This clear dichot-
omy  between ischemia markers and cardiac damage within 
15 minutes of isolated heart perfusion argues against a 
causative role of ischemia in the cardiac destructive effects 
observed with high-dose administration of the peptide.
Discussion
We recently investigated the functional consequences of 
reduced mitochondrial-HKII interactions by using a small 
molecule approach. Specifically, we used a peptide (TAT-
HKII) containing the mitochondrial binding motif of HKII,8 
which has been shown to dislodge HKII from mitochondria in 
intact cells.9 In that study, we abrogated the protective effects 
of IPC on IR injury by low-dose TAT-HKII administration 
and caused rapid myocardial dysfunction and mitochondrial 
disintegration by high-dose TAT-HKII treatment. We attrib-
uted these functional and ultrastructural changes to reduced 
HKII interaction with mitochondria, as evidenced by EM and 
immunogold labeling of HKII. In this issue of Circulation 
Research, Pasdois et al10 report similar functional changes in 
rat hearts but arrive at a very different conclusion with regard 
to underlying mechanisms.
Deleterious Effects of High-Dose TAT-HKII In 
Intact Myocardium: Muscle or Vessel?
A key finding by Pasdois et al is the impairment of vascular 
function by high-dose TAT-HKII administration in the intact 
heart. This translates to a major increase in perfusion pres-
sure (during constant flow conditions) or a decrease in flow 
(during constant pressure perfusion). Indeed, it is conceiv-
able that ischemic injury caused by impaired vascular func-
tion may underlie mitochondrial dysfunction and associated 
electric abnormalities. We addressed this issue directly by 
investigating the impact of low-flow perfusion, endothelin-
mediated vasoconstriction, and high perfusion pressure on 
electrophysiological properties, mitochondrial function, and 
ultrastructure. Finally, we assessed the presence of ischemia 
and associated damage in several groups, including low- and 
high-dose TAT-HKII perfused hearts. We found that neither 
vascular changes nor ischemic damage can explain the acute 
e12  Circulation Research  January 18, 2013
and detrimental effects of TAT-HKII administration in the 
intact heart. However, our present findings do not exclude the 
theoretical possibility that some of the adverse effects of high-
dose TAT-HKII administration may somehow be amplified 
by minor ischemic damage. Nevertheless, we believe that our 
present findings reaffirm the vital importance of maintaining a 
basal level of HKII on cardiac mitochondria to preserve mito-
chondrial energetics, electro-mechanical function, and cardiac 
structure, as we originally concluded.
Abrogation of IPC: Partial Loss of Mitochondrial-
HKII Levels or Silent Ischemia?
Pasdois et al10 argued that the abrogation of IPC with low-dose 
peptide administration may be attributed to ischemia. Using 3 
independent techniques, we were unable to detect ischemia or 
ischemia-mediated dysfunction in the low-dose peptide group, 
arguing strongly against a role for ischemia in the abrogation 
of the protective effects of IPC by low-dose peptide adminis-
tration. However, it is still possible that vascular changes may 
be unmasked by low-dose administration of the peptide during 
the reperfusion phase that follows an ischemic insult, an issue 
that will require direct examination in future studies.
Finally, using cell fractionation and Western blotting tech-
niques on isolated mitochondria, Pasdois et al found that 
TAT-HKII administration did not alter HKII binding to mi-
tochondria. One potential explanation for this discrepancy 
could be their reliance on a short period of peptide adminis-
tration (<9 minutes). The protocol they chose is indeed prob-
lematic considering that the half-time of HK dissociation 
from mitochondria was recently reported to be 8.5 minutes.11 
In addition, the negative findings by Pasdois et al can also be 
explained by previous studies that highlight the importance 
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Figure 2. A, Representative 
action potential traces 
recorded during steady-state 
pacing in TAT-con and TAT-
HKII hearts. Average rate-
dependence of APD90 (B) and 
APD75 (C) in TAT-con and TAT-
HKII groups. D, Representative 
action potential upstrokes 
recorded from equidistant sites 
relative to the pacing electrode 
indicating action potential 
(AP) propagation delays in 
TAT-con and TAT-HKII hearts. 
E, Representative series of 
isopotential contour maps 
recorded every 1 ms from 
TAT-con and TAT-HKII hearts 
indicating sequential spread of 
the AP. F, Average conduction 
velocity in TAT-con and TAT-
HKII hearts. Average Lactate 
production (G), LDH release 
(H) and NADH fluorescence 
levels (I) in 2.5 μmol/L TAT-HKII 
(high-dose peptide group), 
200 nmol/L TAT-HKII (low-dose 
peptide group), 2.5 μmol/L 
TAT-con (control group), 60% 
flow reduction group, 7.5 
nmol/L endothelin-1 group, 
and hypoxia group. One-way 
analysis with Dunnett’s (G, H) 
or Bonferroni (I) post hoc tests. 
*, **, ***, P<0.05, 0.01, or 0.001, 
respectively. LDH indicates 
lactate dehydrogenase; 
NADH, nicotinamide adenine 
dinucleotide; PCL, pacing cycle 
length; TAT-con, transactivating 
transcriptional factor for control 
group; and TAT-HKII, cell 
permeable peptide containing 
hexokinase II mitochondrial 
binding motif.
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Figure 2. A, Representative 
action potential traces 
recorded during steady-state 
pacing in TAT-con and TAT-
HKII hearts. Average rate-
dependence of APD90 (B) and 
APD75 (C) in TAT-con and TAT-
HKII groups. D, Representative 
action potential upstrokes 
recorded from equidistant sites 
relative to the pacing electrode 
indicating action potential 
(AP) propagation delays in 
TAT-con and TAT-HKII hearts. 
E, Representative series of 
isopotential contour maps 
recorded every 1 ms from 
TAT-con and TAT-HKII hearts 
indicating sequential spread of 
the AP. F, Average conduction 
velocity in TAT-con and TAT-
HKII hearts. Average Lactate 
production (G), LDH release 
(H) and NADH fluorescence 
levels (I) in 2.5 μmol/L TAT-HKII 
(high-dose peptide group), 
200 nmol/L TAT-HKII (low-dose 
peptide group), 2.5 μmol/L 
TAT-con (control group), 60% 
flow reduction group, 7.5 
nmol/L endothelin-1 group, 
and hypoxia group. One-way 
analysis with Dunnett’s (G, H) 
or Bonferroni (I) post hoc tests. 
*, **, ***, P<0.05, 0.01, or 0.001, 
respectively. LDH indicates 
lactate dehydrogenase; 
NADH, nicotinamide adenine 
dinucleotide; PCL, pacing cycle 
length; TAT-con, transactivating 
transcriptional factor for control 
group; and TAT-HKII, cell 
permeable peptide containing 
hexokinase II mitochondrial 
binding motif.
of maintaining the tissue intact when studying the subcellular 
localization of proteins whose association with mitochondria 
is highly regulated.12 To achieve this stringent requirement, 
we resorted to EM and immunohistological analysis of HKII 
in perfusion-fixed hearts. Of note, in pilot experiments we 
also were unable to detect TAT-HKII–mediated changes 
in mitoHKII levels using standard techniques (Western 
blotting and HK activity measurements) that necessitate 
membrane fragmentation (data not shown). Because the 
association of HKII with the outer membrane of mitochon-
dria is a dynamic and reversible process, which is likely 
dependent on the in vivo posttranslational status of its mi-
tochondrial binding partner and the outer membrane poten-
tial (through binding to voltage-dependent anion channel), 
it is not surprising that the tissue fractionation process used 
by us in pilot experiments and Pasdois et al markedly dis-
rupts HKII binding to the mitochondrial membrane.
The importance of studying mitoHKII in situ is also re-
flected by the higher concentration threshold required to 
elicit the detrimental effects of TAT-HKII in isolated mito-
chondria (30 μmol/L range) as compared with intact car-
diomyocytes (≈1 μmol/L range).9 Such finding is consistent 
with the notion that the most dynamic and regulated subpop-
ulation of HKII that binds mitochondria in situ is likely to 
be severely disrupted by the artificial process of membrane 
fragmentation used to isolate mitochondria.12 Interestingly, 
John et al11 recently reported HK dissociation on permeabil-
zation of Chinese hamster ovary cells. A similar mechanism 
underlies the observation that although the outer membrane 
of mitochondria in their in situ native environment is highly 
impermeable, it is readily permeabilized by the mitochondri-
al isolation process probably through loss of tubulin binding 
to voltage-dependent anion channel.13 This highlights major 
differences in mitochondrial membrane properties that likely 
affect the association between HKII and mitochondria using 
various techniques.
Finally, one must note that the technique of EM with im-
munogold labeling has clear limitations. For one, it only al-
lows for very limited sampling and semiquantitative analyses, 
issues which we tried to minimize by choosing an identical 
predefined sampling procedure in all groups. We also com-
plemented our histological examinations with integrative 
functional measurements, including electrophysiological and 
mitochondrial imaging tools, lactate production, NADH, and 
LDH release assays. Further refinement of biochemical tools 
for studying mitoHKII localization and displacement will be 
important in future studies because they will further comple-
ment the semiquantitative EM technique.
In conclusion, Pasdois et al report important changes in 
vascular function that are elicited by TAT-HKII administra-
tion. Here, we demonstrate that impaired vascular function 
does not account for mitochondrial dysfunction in the intact 
heart. However, in light of the intriguing findings by Pasdois 
et al, future work directed toward understanding potential 
mechanisms by which HKII subpopulations may regulate 
vascular smooth muscle and endothelial cell function seems 
highly warranted.
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